Dcf Advisers, LLC Altimmune, Inc. Transaction History

Dcf Advisers, LLC

$185 Million
Q2 2024

A detailed history of Dcf Advisers, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 42,868 shares of ALT stock, worth $288,930. This represents 0.15% of its overall portfolio holdings.

Number of Shares

42,868

Previous 96,225 55.45%

Holding current value

$288,930

Previous $979,000 70.89%

% of portfolio

0.15%

Previous 0.5%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$5.91 - $10.23 $315,339 - $545,842	-53,357 Reduced 55.45%	42,868 $285,000
Q1 2024 May 15, 2024	SELL	$8.22 - $13.81 $156,180 - $262,390	-19,000 Reduced 16.49%	96,225 $979,000
Q4 2023 Feb 13, 2024	SELL	$2.14 - $11.62 $10,165 - $55,194	-4,750 Reduced 3.96%	115,225 $1.3 Million
Q2 2023 Aug 09, 2023	BUY	$3.45 - $5.97 $148,350 - $256,710	43,000 Added 55.86%	119,975 $423,000
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $15,523 - $62,355	-3,705 Reduced 4.59%	76,975 $324,000
Q4 2022 Feb 13, 2023	SELL	$8.74 - $16.45 $1.3 Million - $2.44 Million	-148,320 Reduced 64.77%	80,680 $1.33 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $1.13 Million - $2.38 Million	-106,180 Reduced 31.68%	229,000 $2.92 Million
Q2 2022 Aug 11, 2022	BUY	$3.94 - $11.77 $75,569 - $225,748	19,180 Added 6.07%	335,180 $3.92 Million
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $208,270 - $333,585	35,300 Added 12.58%	316,000 $1.92 Million
Q4 2021 Feb 10, 2022	BUY	$8.69 - $12.48 $360,635 - $517,920	41,500 Added 17.35%	280,700 $2.57 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $787,783 - $1.57 Million	93,450 Added 64.12%	239,200 $2.71 Million
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $1.44 Million - $2.4 Million	145,750 New	145,750 $1.44 Million

Others Institutions Holding ALT

# of Institutions

189

Shares Held

42.3M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $330M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account